Skip to main content
Top
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation

Authors: Mariana Toricelli, Fabiana HM Melo, Giovani B Peres, Débora CP Silva, Miriam G Jasiulionis

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Anoikis resistance is one of the abilities acquired along tumor progression. This characteristic is associated with metastasis development, since tumorigenic cells must survive independently of cell-matrix interactions in this process. In our laboratory, it was developed a murine melanocyte malignant transformation model associated with a sustained stressful condition. After subjecting melan-a melanocytes to 1, 2, 3 and 4 cycles of anchorage impediment, anoikis resistant cells were established and named 1C, 2C, 3C and 4C, respectively. These cells showed altered morphology and PMA independent cell growth, but were not tumorigenic, corresponding to pre-malignant cells. After limiting dilution of 4C pre-malignant cells, melanoma cell lines with different characteristics were obtained. Previous data from our group showed that increased Timp1 expression correlated with anoikis-resistant phenotype. Timp1 was shown to confer anchorage-independent growth capability to melan-a melanocytes and render melanoma cells more aggressive when injected into mice. However, the mechanisms involved in anoikis regulation by Timp1 in tumorigenic cells are not clear yet.

Methods

The β1-integrin and Timp1 expression were evaluated by Western blotting and CD63 protein expression by flow cytometry using specific antibodies. To analyze the interaction among Timp1, CD63 and β1-integrin, immunoprecipitation assays were performed, anoikis resistance capability was evaluated in the presence or not of the PI3-K inhibitors, Wortmannin and LY294002. Relative expression of TIMP1 and CD63 in human metastatic melanoma cells was analyzed by real time PCR.

Results

Differential association among Timp1, CD63 and β1-integrins was observed in melan-a melanocytes, 4C pre-malignant melanocytes and 4C11- and 4C11+ melanoma cells. Timp1 present in conditioned medium of melanoma cells rendered melan-a melanocytes anoikis-resistant through PI3-K signaling pathway independently of Akt activation. In human melanoma cell lines, in which TIMP1 and beta-1 integrin were also found to be interacting, TIMP1 and CD63 levels together was shown to correlate significantly with colony formation capacity.

Conclusions

Our results show that Timp1 is assembled in a supramolecular complex containing CD63 and β1-integrins along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway, independently of Akt phosphorylation. In addition, our data point TIMP1, mainly together with CD63, as a potential biomarker of melanoma.
Literature
1.
go back to reference Medic S, Pearce RL, Heenan PJ, Ziman M: Molecular markers of circulating melanoma cells. Pigment Cell Res 2007, 20:80–91.CrossRefPubMed Medic S, Pearce RL, Heenan PJ, Ziman M: Molecular markers of circulating melanoma cells. Pigment Cell Res 2007, 20:80–91.CrossRefPubMed
2.
go back to reference Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, et al.: Molecular classification of melanoma using real-time quantitative reverse transcriptasepolymerase chain reaction. Cancer 2005, 104:1678–1686.CrossRefPubMed Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, et al.: Molecular classification of melanoma using real-time quantitative reverse transcriptasepolymerase chain reaction. Cancer 2005, 104:1678–1686.CrossRefPubMed
3.
go back to reference Chiarugi P, Giannoni E: Anoikis: a necessary death program for anchoragedependent cells. Biochem Pharmacol 2008, 76:1352–1364.CrossRefPubMed Chiarugi P, Giannoni E: Anoikis: a necessary death program for anchoragedependent cells. Biochem Pharmacol 2008, 76:1352–1364.CrossRefPubMed
5.
go back to reference Howlett AR, Bailey N, Damsky C, Petersen OW, Bissell MJ, et al.: Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci 1995, 108:1945–1957.PubMed Howlett AR, Bailey N, Damsky C, Petersen OW, Bissell MJ, et al.: Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci 1995, 108:1945–1957.PubMed
6.
go back to reference Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996, 13:1709–1719.PubMed Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996, 13:1709–1719.PubMed
7.
go back to reference Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, et al.: Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001, 61:1707–1716.PubMed Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, et al.: Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001, 61:1707–1716.PubMed
8.
go back to reference Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, et al.: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59:2724–2730.PubMed Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, et al.: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59:2724–2730.PubMed
9.
go back to reference Wang LH: Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004, 71:361–367.PubMed Wang LH: Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004, 71:361–367.PubMed
10.
go back to reference Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA: Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 2006, 8:231–241.CrossRefPubMedPubMedCentral Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA: Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 2006, 8:231–241.CrossRefPubMedPubMedCentral
11.
go back to reference McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, et al.: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44–48.CrossRefPubMed McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, et al.: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44–48.CrossRefPubMed
12.
go back to reference Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, et al.: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289–2298.CrossRefPubMed Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, et al.: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289–2298.CrossRefPubMed
13.
go back to reference Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995, 1:899–906.PubMed Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995, 1:899–906.PubMed
14.
go back to reference Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, et al.: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898–906.PubMed Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, et al.: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898–906.PubMed
15.
go back to reference Jung KK, Liu XW, Chirco R, Fridman R, Kim HR: Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934–3942.CrossRefPubMedPubMedCentral Jung KK, Liu XW, Chirco R, Fridman R, Kim HR: Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934–3942.CrossRefPubMedPubMedCentral
16.
go back to reference Goodman SL, Picard M: Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 7:405–12.CrossRef Goodman SL, Picard M: Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 7:405–12.CrossRef
17.
go back to reference Ricca TI, Liang G, Suenaga AP, Han SW, Jones PA, et al.: Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol 2009, 2:329–340.CrossRefPubMedPubMedCentral Ricca TI, Liang G, Suenaga AP, Han SW, Jones PA, et al.: Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol 2009, 2:329–340.CrossRefPubMedPubMedCentral
18.
go back to reference Bayascas JR: Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signaling pathways. Cell Cycle 2008, 19:2978–2982.CrossRef Bayascas JR: Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signaling pathways. Cell Cycle 2008, 19:2978–2982.CrossRef
19.
go back to reference Bennett DC, Cooper PJ, Hart IR: A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987, 39:414–418.CrossRefPubMed Bennett DC, Cooper PJ, Hart IR: A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987, 39:414–418.CrossRefPubMed
20.
go back to reference Hua H, Li M, Luo T, Yin Y, Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011, 23:3853–68.CrossRef Hua H, Li M, Luo T, Yin Y, Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011, 23:3853–68.CrossRef
21.
go back to reference Carvalho RF, Dariolli R, Justulin JL, Sugizaki MM, Politi OM, Cicogna AC, Felisbino S, Dal PSM: Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. Int J Exp Pathol 2006, 6:437–443.CrossRef Carvalho RF, Dariolli R, Justulin JL, Sugizaki MM, Politi OM, Cicogna AC, Felisbino S, Dal PSM: Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. Int J Exp Pathol 2006, 6:437–443.CrossRef
22.
go back to reference Jasiulionis MG, Chammas R, Ventura AM, Travassos LR, Brentani RR: Alpha6beta1-Integrin, a major cell surface carrier of beta1–6-branched oligosaccharides, mediates migration of EJ-ras-transformed fibroblasts on laminin-1 independently of its glycosylation state. Cancer Res 1996, 7:1682–9. Jasiulionis MG, Chammas R, Ventura AM, Travassos LR, Brentani RR: Alpha6beta1-Integrin, a major cell surface carrier of beta1–6-branched oligosaccharides, mediates migration of EJ-ras-transformed fibroblasts on laminin-1 independently of its glycosylation state. Cancer Res 1996, 7:1682–9.
23.
go back to reference Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6.CrossRefPubMedPubMedCentral Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6.CrossRefPubMedPubMedCentral
24.
go back to reference Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, et al.: Integrins and signal transduction. Adv Exp Med Biol 2010, 674:43–54.CrossRefPubMed Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, et al.: Integrins and signal transduction. Adv Exp Med Biol 2010, 674:43–54.CrossRefPubMed
25.
go back to reference Pols MS, Klumperman J: Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009, 315:1584–1592.CrossRefPubMed Pols MS, Klumperman J: Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009, 315:1584–1592.CrossRefPubMed
26.
go back to reference Bourboulia D, Stetler-Stevenson W: Matrix Metalloproteinases (MMPs) and Tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010, 3:161–168.CrossRef Bourboulia D, Stetler-Stevenson W: Matrix Metalloproteinases (MMPs) and Tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010, 3:161–168.CrossRef
27.
go back to reference Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM: TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 2004, 64:952–961.CrossRefPubMed Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM: TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 2004, 64:952–961.CrossRefPubMed
28.
go back to reference Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, et al.: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001, 158:1207–1215.CrossRefPubMedPubMedCentral Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, et al.: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001, 158:1207–1215.CrossRefPubMedPubMedCentral
29.
go back to reference Chesler L, Golde DW, Bersch N, Johnson MD: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995, 86:4506–4515.PubMed Chesler L, Golde DW, Bersch N, Johnson MD: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995, 86:4506–4515.PubMed
30.
go back to reference Guedez L, Courtemanch L, Stetler-Stevenson M: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92:1342–1349.PubMed Guedez L, Courtemanch L, Stetler-Stevenson M: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92:1342–1349.PubMed
31.
go back to reference Bloomston M, Shafii A, Zervos EE, Rosemurgy AS: TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002, 102:39–44.CrossRefPubMed Bloomston M, Shafii A, Zervos EE, Rosemurgy AS: TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002, 102:39–44.CrossRefPubMed
32.
go back to reference Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, et al.: Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011, 17:2417–2425.CrossRefPubMedPubMedCentral Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, et al.: Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011, 17:2417–2425.CrossRefPubMedPubMedCentral
33.
go back to reference Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, Jeon SK, Kim HC, Yoo JS, Ko JH: Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression. J Biol Chem 2012, 287:32467–78.CrossRefPubMedPubMedCentral Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, Jeon SK, Kim HC, Yoo JS, Ko JH: Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression. J Biol Chem 2012, 287:32467–78.CrossRefPubMedPubMedCentral
34.
go back to reference Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, et al.: Progression related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999, 30:562–567.CrossRefPubMed Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, et al.: Progression related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999, 30:562–567.CrossRefPubMed
36.
go back to reference Tsagaraki I, Tsilibary EC, Tzinia AK: TIMP-1 interaction with alphavbeta3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF alphainduced apoptosis. Cell Tissue Res 2010, 342:87–96.CrossRefPubMed Tsagaraki I, Tsilibary EC, Tzinia AK: TIMP-1 interaction with alphavbeta3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF alphainduced apoptosis. Cell Tissue Res 2010, 342:87–96.CrossRefPubMed
37.
go back to reference Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006, 25:99–113.CrossRefPubMed Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006, 25:99–113.CrossRefPubMed
38.
go back to reference Sugiura T, Berditchevski F: Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999, 146:1375–1389.CrossRefPubMedPubMedCentral Sugiura T, Berditchevski F: Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999, 146:1375–1389.CrossRefPubMedPubMedCentral
39.
go back to reference Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, et al.: High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4:e5219.CrossRefPubMedPubMedCentral Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, et al.: High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4:e5219.CrossRefPubMedPubMedCentral
40.
go back to reference Berditchevski F: Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001, 114:4143–4151.PubMed Berditchevski F: Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001, 114:4143–4151.PubMed
41.
go back to reference Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, et al.: CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991, 266:3239–3245.PubMed Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, et al.: CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991, 266:3239–3245.PubMed
43.
go back to reference Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME: A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 1997, 272:2595–2598.CrossRefPubMed Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME: A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 1997, 272:2595–2598.CrossRefPubMed
44.
go back to reference Yauch RL, Hemler ME: Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 2000, 351:629–637.CrossRefPubMedPubMedCentral Yauch RL, Hemler ME: Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 2000, 351:629–637.CrossRefPubMedPubMedCentral
45.
go back to reference Yauch RL, Kazarov AR, Desai B, Lee RT, Hemler ME: Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151. J Biol Chem 2000, 275:9230–9238.CrossRefPubMed Yauch RL, Kazarov AR, Desai B, Lee RT, Hemler ME: Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151. J Biol Chem 2000, 275:9230–9238.CrossRefPubMed
46.
go back to reference Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, et al.: Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost 2003, 1:1161–1173.CrossRefPubMed Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, et al.: Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost 2003, 1:1161–1173.CrossRefPubMed
47.
go back to reference Berditchevski F, Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol 1999, 146:477–492.CrossRefPubMedPubMedCentral Berditchevski F, Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol 1999, 146:477–492.CrossRefPubMedPubMedCentral
48.
go back to reference Jang HI, Lee H: A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 2003, 35:317–323.CrossRefPubMed Jang HI, Lee H: A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 2003, 35:317–323.CrossRefPubMed
50.
go back to reference Berditchevski F, Odintsova E: Tetraspanins as regulators of protein trafficking. Traffic 2007, 8:89–96.CrossRefPubMed Berditchevski F, Odintsova E: Tetraspanins as regulators of protein trafficking. Traffic 2007, 8:89–96.CrossRefPubMed
51.
go back to reference Claas C, Stipp CS, Hemler ME: Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001, 276:7974–7984.CrossRefPubMed Claas C, Stipp CS, Hemler ME: Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001, 276:7974–7984.CrossRefPubMed
52.
go back to reference Dorahy DJ, Lincz LF, Meldrum CJ, Burns GF: Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996, 319:67–72.CrossRefPubMedPubMedCentral Dorahy DJ, Lincz LF, Meldrum CJ, Burns GF: Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996, 319:67–72.CrossRefPubMedPubMedCentral
53.
go back to reference McMannus HJ, Alessi DR, Ashby PR, Precott AR, Murray-Tait V, Armit LJ, Arthur JS, Alessi DR: The vivo role PtdIns (3, 4, 5)P3 binding to PDK1 PH domain defined by knokin mutation. EMBO J 2004, 10:2071–82.CrossRef McMannus HJ, Alessi DR, Ashby PR, Precott AR, Murray-Tait V, Armit LJ, Arthur JS, Alessi DR: The vivo role PtdIns (3, 4, 5)P3 binding to PDK1 PH domain defined by knokin mutation. EMBO J 2004, 10:2071–82.CrossRef
54.
go back to reference Bayascas JR, Wullschleger S, Sakamoto K, Garcia-Matinez JM, Clacher C, Komander D, Van Aalten DM, Boini KM, Lang F, Lipina C, Logie L, Sutherland C, Chudek JÁ, Van Diepen JÁ, Voshol PJ, Lucocq JM, Alessi DR: Mutation of the PDK1 domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 2008, 10:3258–72.CrossRef Bayascas JR, Wullschleger S, Sakamoto K, Garcia-Matinez JM, Clacher C, Komander D, Van Aalten DM, Boini KM, Lang F, Lipina C, Logie L, Sutherland C, Chudek JÁ, Van Diepen JÁ, Voshol PJ, Lucocq JM, Alessi DR: Mutation of the PDK1 domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 2008, 10:3258–72.CrossRef
55.
go back to reference Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 3:307–13.CrossRef Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 3:307–13.CrossRef
56.
go back to reference Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 9:2050–6.CrossRef Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 9:2050–6.CrossRef
57.
go back to reference Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA: Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006, 23:7054–8.CrossRef Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA: Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006, 23:7054–8.CrossRef
58.
go back to reference Davidsen ML, Würtz SØ, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U: TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006, 8:1114–20.CrossRef Davidsen ML, Würtz SØ, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U: TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006, 8:1114–20.CrossRef
Metadata
Title
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation
Authors
Mariana Toricelli
Fabiana HM Melo
Giovani B Peres
Débora CP Silva
Miriam G Jasiulionis
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-22

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine